Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4126600)

Published in Exp Dermatol on July 10, 2014

Authors

Kirsten C Webb1, Jonathan M Eby, Vidhya Hariharan, Claudia Hernandez, Rosalie M Luiten, I Caroline Le Poole

Author Affiliations

1: Department of Dermatology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.

Articles cited by this

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72

Innate immune recognition. Annu Rev Immunol (2001) 26.65

CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 8.60

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev (2001) 7.60

Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol (1987) 6.20

Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev (2004) 5.89

Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol (2004) 3.82

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72

Melanocyte biology and skin pigmentation. Nature (2007) 3.43

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98

High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med (1998) 2.58

Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev (2000) 2.43

Heat shock proteins as regulators of the immune response. Lancet (2003) 2.42

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol (1999) 2.12

Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun (2000) 2.10

The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J Biol Chem (2001) 2.04

Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol (2012) 2.02

Toll-like receptors in ischemia-reperfusion injury. Shock (2009) 1.92

MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol (2003) 1.90

Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol (2013) 1.85

Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment. J Am Acad Dermatol (2011) 1.82

Recent advances in the chemistry of melanogenesis in mammals. J Invest Dermatol (1980) 1.77

Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10. J Immunol (2000) 1.77

The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol (1999) 1.73

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol (2011) 1.70

Mammalian tyrosinase--the critical regulatory control point in melanocyte pigmentation. Int J Biochem (1987) 1.63

Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges (2008) 1.61

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Mechanisms for Hsp70 secretion: crossing membranes without a leader. Methods (2007) 1.42

Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest (2003) 1.41

Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol (2000) 1.35

Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol (1996) 1.35

Depigmentation caused by phenolic detergent germicides. Arch Dermatol (1970) 1.34

Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway. J Biol Chem (1998) 1.28

Toll-like receptors in the skin. Semin Immunopathol (2007) 1.27

Occupational vitiligo due to paratertiary butylphenol and homologues. Trans St Johns Hosp Dermatol Soc (1971) 1.22

Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol (2001) 1.21

4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol (2005) 1.20

Hsp70 protects against UVB induced apoptosis by preventing release of cathepsins and cytochrome c in human melanocytes. Carcinogenesis (2006) 1.19

Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol (1993) 1.19

Occupational vitiligo induced by p-tert-butylphenol, a systemic disease? Lancet (1977) 1.17

Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol (2005) 1.16

MITF mediates cAMP-induced protein kinase C-beta expression in human melanocytes. Biochem J (2006) 1.11

HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol (2008) 1.11

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol (2000) 1.10

Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09

Imiquimod induces apoptosis of human melanocytes. Arch Dermatol Res (2009) 1.08

Evaluation of health aspects of kojic acid in food. Regul Toxicol Pharmacol (2001) 1.07

UVA, pheomelanin and the carcinogenesis of melanoma. Pigment Cell Res (2000) 1.05

Novel peptides with tyrosinase inhibitory activity. Peptides (2007) 1.05

Facets of heat shock protein 70 show immunotherapeutic potential. Immunology (2003) 1.04

Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol (2010) 1.02

Imiquimod. Dermatol Clin (2003) 1.02

Immunological pathomechanisms in vitiligo. Expert Rev Mol Med (2001) 1.01

Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol (1977) 1.00

Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol (2010) 0.99

Melanogenesis and melanoma. Pigment Cell Res (2003) 0.98

Decreased regulatory T-cells and CD4(+) /CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res (2013) 0.95

Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel (2003) 0.95

Mechanism of pigment-cell toxicity produced by hydroxyanisole. J Pathol (1970) 0.95

Tyrosinase autoactivation and the chemistry of ortho-quinone amines. Acc Chem Res (2003) 0.93

The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity. J Invest Dermatol (2000) 0.93

Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol (2010) 0.93

New insights on the structure of the mouse silver locus and on the function of the silver protein. Pigment Cell Res (2000) 0.91

The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators. J Clin Aesthet Dermatol (2010) 0.91

Audiological abnormalities in patients with vitiligo. Clin Exp Dermatol (2006) 0.90

Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. J Invest Dermatol (2008) 0.90

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol (2000) 0.86

A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity. Chem Res Toxicol (2009) 0.86

Depigmentation therapies in vitiligo. Indian J Dermatol Venereol Leprol (2011) 0.85

Clinical pattern of ocular manifestations in vitiligo. J Indian Med Assoc (2003) 0.83

Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol (2006) 0.82

Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment. Melanoma Res (2011) 0.81

Inhibitory effects of some flavonoids on the activity of mushroom tyrosinase. Biochemistry (Mosc) (2003) 0.81

Cerebral neurons and glial cell types inducing heat shock protein Hsp70 following heat stress in the rat. Prog Brain Res (2007) 0.81

Occupational vitiligo due to unsuspected presence of phenolic antioxidant byproducts in commercial bulk rubber. J Occup Med (1988) 0.79

Clinical analysis of hearing levels in vitiligo patients. Eur J Dermatol (2008) 0.79

Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo. Clin Exp Dermatol (2013) 0.78

Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies. Mol Biosyst (2006) 0.78

Tyrosinase autoactivation and the problem of the lag period. Pigment Cell Res (1998) 0.77

A mouse model of vitiligo induced by monobenzone. Exp Dermatol (2013) 0.76

Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin. Exp Dermatol (2006) 0.75

Articles by these authors

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res (2007) 3.66

Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66

Telomerase levels control the lifespan of human T lymphocytes. Blood (2003) 1.59

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res (2011) 1.50

A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol (2013) 1.50

Progression of undiagnosed cutaneous T-cell lymphoma during efalizumab therapy. Arch Dermatol (2009) 1.46

Spanish-speaking patient health educational preferences. Arch Dermatol (2011) 1.39

Medical student detection of melanoma: clinical skills. Arch Dermatol (2010) 1.39

Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun (2008) 1.31

Notch signaling regulates mouse and human Th17 differentiation. J Immunol (2011) 1.21

4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol (2005) 1.20

Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev (2006) 1.12

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 1.12

HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol (2008) 1.11

Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09

First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res (2010) 0.96

Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol (2006) 0.95

Cervical cancer vaccines: recent advances in HPV research. Viral Immunol (2003) 0.95

A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94

Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol (2010) 0.93

Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res (2011) 0.92

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89

A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. Am J Respir Cell Mol Biol (2012) 0.89

T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity. Int Rev Immunol (2006) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci (2003) 0.88

Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol (2009) 0.88

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res (2004) 0.87

Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo. Exp Dermatol (2011) 0.85

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83

Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. Anticancer Res (2011) 0.83

Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis. Am J Pathol (2013) 0.82

Heparin-induced bullous hemorrhagic dermatosis. Cutis (2013) 0.82

Renal angiomyolipoma, fat-poor variant--a clinicopathologic mimicker of malignancy. Virchows Arch (2013) 0.82

De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation. Cancer Res (2009) 0.82

Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment. Melanoma Res (2011) 0.81

Risk factors for infection after cardiovascular surgery in children in Argentina. Braz J Infect Dis (2009) 0.79

Expression of gp100 and CDK2 in melanoma cells is not co-regulated by a shared promoter region. Pigment Cell Res (2004) 0.79

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother (2008) 0.79

Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress. Pigment Cell Melanoma Res (2014) 0.79

Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP. In Vitro Cell Dev Biol Anim (2008) 0.79

Erythromycin-resistant Streptococcus pyogenes in Argentina. Medicina (B Aires) (2004) 0.79

Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells. Eur J Immunol (2012) 0.79

Contact leukoderma after application of a compounded phenol cream and narrowband-UVB. Eur J Dermatol (2008) 0.78

Genital ulcers associated with Epstein-Barr virus. Cutis (2013) 0.78

Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. Pigment Cell Melanoma Res (2014) 0.78

Pain management in dermatologic procedures: before and after. Dermatol Surg (2012) 0.77

The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo. Pigment Cell Melanoma Res (2014) 0.77

Acquired pincer nail deformity associated with renal failure. J Clin Aesthet Dermatol (2011) 0.75

Pulmonary fungal infection diagnosis in chronic granulomatous disease patients. Pediatr Pulmonol (2007) 0.75

Contact dermatitis to white petrolatum. Skinmed (2004) 0.75

Vitiligo treatment demystified: a flowchart for stratified treatment approaches. Exp Dermatol (2014) 0.75

Use of a melanoma simulation model in a dermatology objective structured clinical examination station. Med Teach (2014) 0.75

Topical and light-based treatments for basal cell carcinoma. Semin Cutan Med Surg (2003) 0.75

Acquired microcystic lymphatic malformation of the distal upper extremity mimicking verrucae vulgaris. Pediatr Dermatol (2013) 0.75

A Systematic Review of Team Training in Health Care: Ten Questions. Jt Comm J Qual Patient Saf (2017) 0.75

A review of hair care products for black individuals. Cutis (2014) 0.75

Skin immune system. Cancer Treat Res (2009) 0.75